203 related articles for article (PubMed ID: 24099551)
1. Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers.
Fischer A; Jönsson M; Hjelmström P
Drug Dev Ind Pharm; 2015 Jan; 41(1):79-84. PubMed ID: 24099551
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers.
Jönsson M; Mundin G; Sumner M
Eur J Pharm Sci; 2018 Sep; 122():125-133. PubMed ID: 29940217
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
Chiang CN; Hawks RL
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.
Harris DS; Mendelson JE; Lin ET; Upton RA; Jones RT
Clin Pharmacokinet; 2004; 43(5):329-40. PubMed ID: 15080765
[TBL] [Abstract][Full Text] [Related]
5. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
6. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
Middleton LS; Nuzzo PA; Lofwall MR; Moody DE; Walsh SL
Addiction; 2011 Aug; 106(8):1460-73. PubMed ID: 21395892
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.
Lintzeris N; Leung SY; Dunlop AJ; Larance B; White N; Rivas GR; Holland RM; Degenhardt L; Muhleisen P; Hurley M; Ali R
Drug Alcohol Depend; 2013 Jul; 131(1-2):119-26. PubMed ID: 23317685
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.
Ciraulo DA; Hitzemann RJ; Somoza E; Knapp CM; Rotrosen J; Sarid-Segal O; Ciraulo AM; Greenblatt DJ; Chiang CN
J Clin Pharmacol; 2006 Feb; 46(2):179-92. PubMed ID: 16432270
[TBL] [Abstract][Full Text] [Related]
10. Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.
Soyka M
Expert Opin Drug Deliv; 2012 Nov; 9(11):1409-17. PubMed ID: 23013384
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine/Naloxone (Zubsolv
Heo YA; Scott LJ
CNS Drugs; 2018 Sep; 32(9):875-882. PubMed ID: 30117074
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence.
Bell J; Byron G; Gibson A; Morris A
Drug Alcohol Rev; 2004 Sep; 23(3):311-7. PubMed ID: 15370011
[TBL] [Abstract][Full Text] [Related]
13. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
Strain EC; Harrison JA; Bigelow GE
Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
McAleer SD; Mills RJ; Polack T; Hussain T; Rolan PE; Gibbs AD; Mullins FG; Hussein Z
Drug Alcohol Depend; 2003 Oct; 72(1):75-83. PubMed ID: 14563545
[TBL] [Abstract][Full Text] [Related]
15. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States.
Asche CV; Clay E; Kharitonova E; Zah V; Ruby J; Aballéa S
J Med Econ; 2015; 18(8):600-11. PubMed ID: 25851505
[TBL] [Abstract][Full Text] [Related]
16. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
Larance B; Lintzeris N; Ali R; Dietze P; Mattick R; Jenkinson R; White N; Degenhardt L
Drug Alcohol Depend; 2014 Mar; 136():21-7. PubMed ID: 24461476
[TBL] [Abstract][Full Text] [Related]
17. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder.
Dong R; Wang H; Li D; Lang L; Gray F; Liu Y; Laffont CM; Young M; Jiang J; Liu Z; Learned SM
Drugs R D; 2019 Sep; 19(3):255-265. PubMed ID: 31197606
[TBL] [Abstract][Full Text] [Related]
19. Preference for buprenorphine/naloxone and buprenorphine among patients receiving buprenorphine maintenance therapy in France: a prospective, multicenter study.
Daulouède JP; Caer Y; Galland P; Villeger P; Brunelle E; Bachellier J; Piquet JM; Harbonnier J; Leglise Y; Courty P
J Subst Abuse Treat; 2010 Jan; 38(1):83-9. PubMed ID: 19800758
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
Compton P; Ling W; Moody D; Chiang N
Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
